We are live on ! Find out more
REPL icon

Replimune Group

127 hedge funds and large institutions have $971M invested in Replimune Group in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 51 increasing their positions, 42 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more call options, than puts

Call options by funds: $43.6M | Put options by funds: $33.5M

21% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 42

1.79% more ownership

Funds ownership: 94.5%96.29% (+1.8%)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

10% less funds holding

Funds holding: 141127 (-14)

23% less capital invested

Capital invested by funds: $1.27B → $971M (-$296M)

61% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 23

Holders
127
Holders Change
-14
Holders Change %
-9.93%
% of All Funds
2.02%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
9
Increased
51
Reduced
42
Closed
23
Calls
$43.6M
Puts
$33.5M
Net Calls
+$10.1M
Net Calls Change
+$14.9M
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$99.1M +$1.18M +60,187 +1%
BBA
2
Baker Bros. Advisors
New York
$78.3M
RG
3
Redmile Group
California
$71.2M -$5.04M -256,611 -6%
BlackRock
4
BlackRock
New York
$67.7M +$9.11M +463,900 +13%
OFM
5
Omega Fund Management
Massachusetts
$51.4M
Vanguard Group
6
Vanguard Group
Pennsylvania
$44.4M +$4.76M +242,220 +10%
State Street
7
State Street
Massachusetts
$40.6M +$5.53M +281,664 +13%
Janus Henderson Group
8
Janus Henderson Group
United Kingdom
$37.1M +$42.2M +2,149,008 +11,950%
BI
9
BVF Inc
California
$36.7M
AVLSA
10
Atlas Venture Life Science Advisors
Massachusetts
$35.9M
CCM
11
Camber Capital Management
Massachusetts
$34.2M +$8.84M +450,000 +29%
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$24.5M +$2.86M +145,576 +11%
Loomis, Sayles & Company
13
Loomis, Sayles & Company
Massachusetts
$22.1M +$2.03M +103,223 +9%
Fidelity Investments
14
Fidelity Investments
Massachusetts
$21.7M -$5.42M -275,885 -18%
Citadel Advisors
15
Citadel Advisors
Florida
$20.5M +$1.2M +60,917 +5%
EA
16
Emerald Advisers
Pennsylvania
$18M -$663K -33,763 -3%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$17.3M +$4.08M +207,515 +26%
EMFAT
18
Emerald Mutual Fund Advisers Trust
Pennsylvania
$15M -$525K -26,742 -3%
T. Rowe Price Investment Management
19
T. Rowe Price Investment Management
Maryland
$12.4M
Marshall Wace
20
Marshall Wace
United Kingdom
$11.8M -$10.7M -543,771 -44%
GPP
21
Great Point Partners
Connecticut
$10.9M +$12.5M +638,495 New
CS
22
Candriam SCA
Luxembourg
$10.5M
Goldman Sachs
23
Goldman Sachs
New York
$9.57M -$1.05M -53,443 -9%
Amundi
24
Amundi
France
$8.87M +$2.55M +130,041 +29%
SI
25
Sofinnova Investments
California
$8.62M +$3.04M +154,955 +44%

REPL Hedge Fund Activity: Q3 2023 in Review

127 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Replimune Group (REPL) for Q3 2023, worth a combined $971M — down 23% from $1.27B a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of REPL and 9 opened new positions — a net loss of 14 holders — while 42 trimmed existing stakes and 51 added.

The largest buyer was Janus Henderson Group, adding an estimated $42.2M. The largest seller was Lord, Abbett & Co, cutting an estimated $16.8M.

  • 127 institutional investors held Replimune Group (REPL) as of Q3 2023, down from 141 in Q2 2023.
  • Funds reported $971M of Replimune Group stock for Q3 2023, down 23% quarter-over-quarter.
  • 9 funds opened new Replimune Group positions in Q3 2023 and 23 closed out, a net change of -14 holders.
  • The largest Replimune Group buyer in Q3 2023 was Janus Henderson Group, an estimated $42.2M added.
  • The largest Replimune Group seller in Q3 2023 was Lord, Abbett & Co, an estimated $16.8M sold.

Based on aggregated 13F filings for Q3 2023.